A Trial Comparing the Pharmacokinetics of Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Trial Profile

A Trial Comparing the Pharmacokinetics of Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs Nonacog beta pegol (Primary) ; Eftrenonacog alfa
  • Indications Haemophilia B
  • Focus Pharmacokinetics
  • Acronyms paradigm™7
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 05 Apr 2017 Planned End Date changed from 18 Sep 2017 to 18 Dec 2017.
    • 14 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top